Current Trends in RNA Virus Vaccines
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 46319
Special Issue Editor
Interests: flavivirus; Coronavirus; zoonosis; virus-host interactions; antivirals; vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
As Guest Editor of the Pharmaceuticals Special Issue “Current trends in RNA virus vaccines” (https://www.mdpi.com/journal/pharmaceuticals/special_issues/current_trends_in_RNA_virus_vaccines), I would like to invite you to contribute with an original report, original observation, commentary, or review.
As you are perfectly aware, RNA viruses are one of the leading causes of infectious animal, human and zoonotic diseases worldwide, affecting millions of people, as clearly exemplified by the current devastating epidemic of the recently identified SARS-CoV-2 that has already infected more than 50 million people and caused more than 1.2 million deaths. Vaccine development has had an enormous impact on overcoming the global burden of diseases throughout the use of a vast number of classical and state of the art approaches, from purified inactivated and live attenuated viruses, to nucleic acid (DNA or RNA)-based candidates, virus-like particles, subunit elements, and recombinant viruses. However, licensed vaccines are only available for a few RNA viruses, and, thus, new and improved vaccines are necessary for many others. Therefore, to achieve a more comprehensive understanding of the current trends in vaccine development against RNA viruses, this Pharmaceuticals Special Issue is dedicated to recent developments and technological progress in vaccinology against RNA viruses, and the molecular mechanisms and immune responses involved. Based on your extensive experience and your recent publications, it will be our honor to publish your quality work on this field. We sincerely hope that you will be able to accept our invitation. If you are able to contribute, please let us know at your earliest convenience and we will provide you with additional details.
Prof. Dr. Juan Carlos Saiz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA viruses
- vaccines
- adjuvants
- immune response
- cell–host interactions